Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine

• DOI: 10.1007/s10194-007-0417-4
• Publication Date: 2007-10-22T20:19:34Z
• Authors: Mario Guidotti; Michela Mauri; Caterina Barrilà; Francesca Guidotti; Carlo Belloni
• Keywords: Naproxen Sodium; Triptans; Menstruation

Acute treatment of menstrual migraine (MM) attacks is often incomplete and unsatisfactory, perimenstrual prophylaxis with triptans, oestrogen supplementation or naproxen sodium may be needed for decreasing frequency severity the attack. In this pilot, open-label, non-randomised, parallel group study we evaluated, in 38 women a history MM, efficacy frovatriptan (n=14) 2.5 mg per os transdermal oestrogens (n=10) 25 μg 500 once-daily short-term prevention MM. All treatments were administered morning 6 days, beginning 2 days before expected onset headache. asked to fill diary card, absence (baseline) under treatment, order score headache severity. reported at least one episode MM baseline. During all patients taking 13 out 14 (93%) had attack (p=0.424). Daily incidence was significantly (p=0.045) lower than NS. At baseline, overall median 4.6, 4.2 4.3 subsequently treated frovatriptan, sodium, respectively (p=0.819). (2.5) (3.0) (3.9, p=0.049). This evident also each single day observation (p=0.016). Among differences particularly subgroup true (n=22) vs. sodium. suggests that more effective based on